Laura D'Erasmo (@Lauraderasmo) profile picture

MD, PhD

Joined April 2022
Photo by Laura D'Erasmo (@Lauraderasmo)Photo by Laura D'Erasmo (@Lauraderasmo)Photo by Laura D'Erasmo (@Lauraderasmo)Photo by Laura D'Erasmo (@Lauraderasmo)Photo by Laura D'Erasmo (@Lauraderasmo)Photo by Laura D'Erasmo (@Lauraderasmo)Photo by Laura D'Erasmo (@Lauraderasmo)Photo by Laura D'Erasmo (@Lauraderasmo)Photo by Laura D'Erasmo (@Lauraderasmo)Photo by Laura D'Erasmo (@Lauraderasmo)
#Hypertriglyceridemia is independently associated with risk of atherosclerotic events, even when LDL-cholesterol levels appear controlled. This #INTERASPIRE study determined the frequency of HTG and residual combined dyslipidemia and their related factors in patients with coronary heart disease (CHD) from 13 countries across six World Health Organization (WHO) regions. Read more: bit.ly/4kDPQSn
5
13
779
“Lipid-Lowering Therapy and Cardiovascular Prevention in Elderly” A narrative review on one of the great challenges of our times. rdcu.be/el2zv
1
4
45
New @lipidjournal article!📄 Check out our latest open access article on lomitapide treatment in patients with HoFH. Read it now👉ow.ly/cAV150VvTs5
2
8
18
1,178
Authors: Marcello Arca, MD, @Lauraderasmo, Marina Cuchel, MD, PhD, Dirk Blom, PhD, Jaimini Cegla, PhD, FRCPath, P. Barton Duell, MD, @rauldsf_santos, Sallyann O'Brien, PhD
1
3
428
📣 It’s spring time! 📆 6-8 April 2025 🎂 X edizione del meeting dedicato ai giovani ricercatori clinici e di base di #SISA #SIMI #SIIA #SID #SIPREC #SIGG. Let’s meet, discuss, joint and enjoy! sisa.it/SprMtng2025
3
3
5
164
Laura D'Erasmo retweeted
Approximately 1 in 5 patients with possible FH who received any form of outreach as part of a QI program had a meaningful change in the management. Various process factors resulted in improved care. ow.ly/Ei1l50VhJg0 @dramitkhera
3
9
744
Delighted to have presented the first Phase 2 trial of solbinsiran a siRNA targeting ANGPTL3 a key regular of Triglyceride metabolism. Despite ldl lowering patients with high TG have a high residual risk of CVD.
3
18
1
66
3,559
The EAS FHSC is the largest only global registry of FH. I conceived the idea in 2015 and with a few colleagues started this. 10 years on it’s really starting to deliver important insights . Great editorial
Management of obesity in patients living with heterozygous familial hypercholesterolaemia: read the editorial in #EHJ! academic.oup.com/eurheartj/a… #obesity #cardiotwitter #EHJ @ESC_journals @escardio
7
30
1,916
Laura D'Erasmo retweeted
Why some heavy drinkers don't develop cirrhosis ? The answer is in the genes. This great article summarizes the hallmark research hits implicating PNPLA3 gene variations and individual susceptibility to alcohol-related cirrhosis. t.ly/os6Rf
2
45
1
124
9,739
Laura D'Erasmo retweeted
Wear red to be seen, to be counted, to be heard, to make an impact. At Atherosclerosis we wear red every day #WearRedDay @GoRedForWomen #GoRedforWomen #nationalgoredday @American_Heart @society_eas @atherosociety
1
8
1
20
1,613
Spotted in the very first EAS-LIPRA newsletter 📬 Great contribution @brettsmansfield! Can’t wait to read the preliminary results of your investigation on Lp(a) within African populations @society_eas #LIPRA #EASSoMe
2
1
8
703
Our last effort is now available on @ATHjournal. Understanding the differences in clinical and therapeutic management for men and women. @j_rvl @kiaretta21 @arturocesaro @Tramontano_D atherosclerosis-journal.com/…
3
11
656
The role of lipids in cardiovascular disease is well established through epidemiological studies; however, the underlying pathophysiological mechanisms remain largely unknown. Numerous recent studies focus on the deleterious impact of lipids on cardiovascular health. In this lecture, Prof. Jan Borén presents a state-of-the-art overview of current knowledge in the field: eas.to/OpenNov24 @ProfKausikRay @KatiOorni
2
5
15
1,118